Cargando…
The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties
Tigecycline (TIG), the first member of glycylcycline bacteriostatic agents, has been approved to treat complicated infections in the clinic because of its expanded-spectrum antibiotic potential. Recently, an increasing number of studies have emphasized the anti-tumor effects of TIG. The inhibitory e...
Autores principales: | Xu, Zhijie, Yan, Yuanliang, Li, Zhi, Qian, Long, Gong, Zhicheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133451/ https://www.ncbi.nlm.nih.gov/pubmed/27994551 http://dx.doi.org/10.3389/fphar.2016.00473 |
Ejemplares similares
-
SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3β/β-Catenin Signaling Axis
por: Dai, Shuang, et al.
Publicado: (2018) -
Corrigendum: SCD1 Confers Temozolomide Resistance to Human Glioma Cells Via the Akt/GSK3β/β-Catenin Signaling Axis
por: Dai, Shuang, et al.
Publicado: (2019) -
Exosome-based immunotherapy: a promising approach for cancer treatment
por: Xu, Zhijie, et al.
Publicado: (2020) -
Mechanism of Abnormal Coagulation Induced by Tigecycline in Cancer Patients
por: Sun, Li-Hua, et al.
Publicado: (2022) -
Neopeltolide and its synthetic derivatives: a promising new class of anticancer agents
por: Peña-Corona, Sheila I., et al.
Publicado: (2023)